Trial reportThe journal of behavioral health services & research2008
Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia.
Trial report in The journal of behavioral health services & research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 5 syntheses or guidelines pooled it, 24 citations in OpenAlex.
- Interventions for obtaining and maintaining employment in adults with severe mental illness, a network meta-analysis.The Cochrane database of systematic reviews · 2017Pooled it
- Perphenazine for schizophrenia.The Cochrane database of systematic reviews · 2015Pooled it
- Quetiapine versus other atypical antipsychotics for schizophrenia.The Cochrane database of systematic reviews · 2013Pooled it
- Antipsychotic drug treatment for elderly people with late-onset schizophrenia.The Cochrane database of systematic reviews · 2012Pooled it
- Ziprasidone versus other atypical antipsychotics for schizophrenia.The Cochrane database of systematic reviews · 2009Pooled it
- Can a nonequivalent choice of dosing regimen bias the results of flexible dose double blind trials? The CATIE schizophrenia trial.Schizophrenia research · 2009Trial
- Factors related to employment across vocational levels in patients with schizophrenia: focus on subminimum wage non-competitive employment.BMC psychiatry · 2026Article
- Employment and the associated impact on quality of life in people diagnosed with schizophrenia.Neuropsychiatric disease and treatment · 2015Review
- Change in level of productivity in the treatment of schizophrenia with olanzapine or other antipsychotics.BMC psychiatry · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Employment has been increasingly recognized as an important goal for individuals with schizophrenia. Previous research has shown mixed results on the relationship of specific antipsychotic medications to employment outcomes, with some studies finding greater benefits for second-generation antipsychotic medications (SGAs) over first-generation antipsychotic medication (FGAs). A randomized controlled trial (CATIE) examined medication assignment and both employment outcomes and participation in psychosocial rehabilitation (PSR) among 1,121 individuals with a diagnosis of schizophrenia randomized to SGAs (olanzapine, quetiapine, risperidone, ziprasidone) or one FGA (perphenazine). Service use and employment were assessed at quarterly interviews. There were no differences between medication groups on employment outcomes or participation in PSR. Consistent with other CATIE results, there were no differences in employment or participation in PSR among these five medications, including the FGA perphenazine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.